Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shen Lu

Showing results (211-220 of 237) with videos related to

Pageof 24
Sort By:
Frontiers in Oncology|March 25, 2026
Correction: Part II: consensus statements and expert recommendations for BRCA-associated breast cancer in the Asia-Pacific region: clinical managementYeon Hee Park, Soo Chin Lee, Christian F Singer, et al.
Plos One|April 25, 2015
High Prevalence of the BIM Deletion Polymorphism in Young Female Breast Cancer in an East Asian CountryChing-Hung Lin, Chen-Yang Shen, Jih-Hsiang Lee, et al.
Cancer Treatment and Research Communications|March 26, 2025
A retrospective study to investigate the prevalence and describe the clinicopathological characteristics, treatments, and outcomes of HER2-low Breast Cancer in TaiwanKuo-Ting Lee, Po-Hsiang Huang, Chih-Yi Hsu, et al.
Breast Cancer Research : BCR|January 16, 2021
A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancerPeter Schmid, Marie-Paule Sablin, Jonas Bergh, et al.
World Journal of Gastroenterology|September 9, 2005
Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patientsWen-Pin Su, Chi-Chung Wen, Chao-A Hsiung, et al.
Nature Communications|May 9, 2025
Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohortXichun Hu, Qingyuan Zhang, Tao Sun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 12, 2024
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01Aditya Bardia, Komal Jhaveri, Seock-Ah Im, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 21, 2024
Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast CancerYen-Shen Lu, Eznal Izwadi Bin Mohd Mahidin, Hamdy Azim, et al.
Future Oncology (London, England)|June 30, 2023
TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancerAditya Bardia, Komal Jhaveri, Kevin Kalinsky, et al.
JAMA Oncology|December 21, 2023
Whole-Brain Radiotherapy Alone vs Preceded by Bevacizumab, Etoposide, and Cisplatin for Untreated Brain Metastases From Breast Cancer: A Randomized Clinical TrialTom Wei-Wu Chen, Ming-Shen Dai, Ling-Ming Tseng, et al.
Pageof 24

Showing results (211-220 of 237) with videos related to

Sort By:
Pageof 24
Frontiers in Oncology|March 25, 2026
Correction: Part II: consensus statements and expert recommendations for BRCA-associated breast cancer in the Asia-Pacific region: clinical managementYeon Hee Park, Soo Chin Lee, Christian F Singer, et al.
Plos One|April 25, 2015
High Prevalence of the BIM Deletion Polymorphism in Young Female Breast Cancer in an East Asian CountryChing-Hung Lin, Chen-Yang Shen, Jih-Hsiang Lee, et al.
Cancer Treatment and Research Communications|March 26, 2025
A retrospective study to investigate the prevalence and describe the clinicopathological characteristics, treatments, and outcomes of HER2-low Breast Cancer in TaiwanKuo-Ting Lee, Po-Hsiang Huang, Chih-Yi Hsu, et al.
Breast Cancer Research : BCR|January 16, 2021
A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancerPeter Schmid, Marie-Paule Sablin, Jonas Bergh, et al.
World Journal of Gastroenterology|September 9, 2005
Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patientsWen-Pin Su, Chi-Chung Wen, Chao-A Hsiung, et al.
Nature Communications|May 9, 2025
Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohortXichun Hu, Qingyuan Zhang, Tao Sun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 12, 2024
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01Aditya Bardia, Komal Jhaveri, Seock-Ah Im, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 21, 2024
Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast CancerYen-Shen Lu, Eznal Izwadi Bin Mohd Mahidin, Hamdy Azim, et al.
Future Oncology (London, England)|June 30, 2023
TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancerAditya Bardia, Komal Jhaveri, Kevin Kalinsky, et al.
JAMA Oncology|December 21, 2023
Whole-Brain Radiotherapy Alone vs Preceded by Bevacizumab, Etoposide, and Cisplatin for Untreated Brain Metastases From Breast Cancer: A Randomized Clinical TrialTom Wei-Wu Chen, Ming-Shen Dai, Ling-Ming Tseng, et al.
Pageof 24